iShares Silver Trust vs GeneDx Holdings Corp — how do they compare? iShares Silver Trust trades at $61.11, while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). Which is the better fit depends on your goals.
| SLV | WGS | |
|---|---|---|
52-Week High | $105.57 | $167.51 |
52-Week Low | $37.41 | $34.51 |
Market Cap | — | $2.56B |
Sector | — | Technology |
Enterprise Value | — | $2.60B |
Signals from Pluang's Aura AI — not financial advice
SLV, the iShares Silver Trust ETF, trades at $59.37, down 0.75% on the day, with a bearish technical signal driven by moving averages. The ETF lacks traditional valuation metrics like P/E or P/B as it tracks physical silver. Recent news highlights silver's volatility amid Fed policy uncertainty and geopolitical tensions, with institutional buying noted in Q2 2026 filings.
Outlook remains mixed: silver's structural deficit supports prices, but Fed rate risks and dollar fluctuations pose headwinds. Investors face volatility from industrial demand shifts and inflation data, with technical resistance near $60–$61 capping near-term upside.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Trailing returns across standard periods
Latest headlines on both assets
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →